Parker Waichman LLP

FDA Plan to Ease Off-Label Marketing Rules Draws Criticism

Medical researchers are concerned over some proposed guidelines issued from the US Food and Drug Administration (FDA) that would allow companies to market more drugs for unapproved uses—a move seen as a reversal, by some—according to a researcher from the Stanford University School of Medicine.  Randall Stafford, MD, PhD, associate professor of medicine at the […]

Medical researchers are concerned over some proposed guidelines issued from the US Food and Drug Administration (FDA) that would allow companies to market more <"https://www.yourlawyer.com/practice_areas/defective_drugs">drugs for unapproved uses—a move seen as a reversal, by some—according to a researcher from the Stanford University School of Medicine.  Randall Stafford, MD, PhD, associate professor of medicine at the Stanford Prevention Research Center, criticized the draft guidelines.  Guidelines are open to public comment through April 21 and lessen the FDA’s already limited authority over the marketing of drugs for off-label uses, according to Stafford, whose editorial is to be published in the April 3 issue of The New England Journal of Medicine.

It is generally assumed that medications prescribed by US doctors always receive FDA approval; however, the FDA approves drugs for specific purposes and physicians can prescribe use drugs “off-label” for medical conditions for which the drugs were not approved by the FDA.  Off-label prescribing for medical conditions not scrutinized during the FDA approval process occurs routinely and off-label prescribing is legal and—often—is good medicine, according to Stafford, who directs Stanford’s Program on Prevention Outcomes and Practices.  Once the FDA approves a drug for one condition, physicians are free to prescribe that drug for any reason.
The problem occurs because what is known about a drug in one situation may not apply to other clinical scenarios.  For instance, Stafford explained, the use antidepressants in children and the use of antipsychotic medications for dementia.  “The FDA should not suddenly start telling physicians how to practice.  Physician judgment is critical, especially when approved therapies have not succeeded.  Off-label prescribing can be an important tool in such cases,” he said. “But in other cases, off-label prescribing has become first-line therapy even in the absence of strong evidence of benefits and safety.  This is problematic.”  Stafford feels these situations suggest improved off-label drug evaluation and regulation is needed and that—in the best case—a drug maker would return to the FDA with additional clinical studies and to obtain supplemental approval for a new clinical use.

Off-label drug use is common; however, FDA applications seeking approval of new uses are rare, said Stafford.  And, although FDA regulations restrict drug manufacturers from overtly promoting drugs for unapproved conditions, manufacturers are legally able to share educational materials with physicians, generally in the form of published journal articles.  According to current FDA guidelines, this is acceptable if the manufacturer submits the articles to the FDA for review and pursues formal FDA approval for the new use. FDA enforcement is limited, said Stafford and the new draft guidelines further restrict FDA involvement by eliminating both these requirements and reduce remaining policies to non-binding recommendations.

One of the proposed guidelines’ major problems according to Stafford, would be allowing drug manufacturers to skip obtaining approval for potentially lucrative drug uses.  Companies might seek approval only for a narrower, more easily and less expensively tested, use, sponsoring research on more commercially promising uses never evaluated by the FDA. Stafford warned that this might encourage widespread treatment of conditions with drugs never approved by the FDA for those purposes.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
First off I have to say thank you to Linda Luckman and Brett Zekowski. Extra kudos to Linda, thank you for your patience, I know I called you so many times, and you were pleasant all the time , answered my questions, and called me back EVERYTIME , you said you would, or if I left a message for you..Parker Waichman, KEEP HER, she's truly an asset to the company. I couldn't wait to meet that lovely lady, was one of the people I had to see.and what a lovely lady indeed...Anyway, let me get on with the review...I am very happy to have Parker Watchman represent me as this company is an excellent company who kept me informed along the way, receptionists answering the phones friendly, and I truly felt the company was doing what was best for me..thank you guys, great job!! If you need a lawyer, I highly recommend Parker Waichman!!
Joseph Monroe
5 years ago
5 Star Reviews 150
I am happy to choose Parker Waichman to handle my case. They are very professional and attentive, they always answer any questions I have. I also thank Denny Tang, Kathy Núñez and Jorge Peniche for making me feel comfortable with their help. Thank you for everything you are doing for me.
Francisco Aviles
5 years ago
5 Star Reviews 150
I contacted Parker Waichman a little over 2 years ago in regards to a WTC claim. PW informed me, at that time, that I had to register with the WTC Health Plan. Well, this led to 2 years of patience, health exams and time (on both my part and PW's part) to have my health conditions certified. Directly following certification, Nicole Copertino quickly pushed my claim through with diligence and expert professionalism. I truly appreciate her care and concern for me. I look forward to a positive outcome. Duly note her expertise and talent. Thank You Nicole. Looking forward to working with you through to the outcome.
Lee Pinckney
9 months ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038